PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1378697
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1378697
North America Sickle Cell Disease Market, By Disease Type, By Drug Type, By Distribution Channel
The North America sickle cell disease market is estimated to be valued at US$ 1,036.5 million in 2023 and is expected to exhibit a CAGR of 16.2% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 1,036.5 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 16.20% | 2030 Value Projection: | US$ 2,970.5 Mn |
Sickle Cell Disease (SCD) is a group of inherited red blood cell disorders. Red blood cells contain hemoglobin, a protein that carries oxygen. Healthy red blood cells are round, and they move through small blood vessels to carry oxygen to all parts of the body. In someone who has SCD, the hemoglobin is abnormal, which causes the red blood cells to become hard and sticky and look like a C-shaped farm tool called a "sickle." Sickle cells die early, which causes a constant shortage of red blood cells. Also, when they travel through small blood vessels, they get stuck and clog the blood flow. This can cause pain and other serious complications (health problems) such as infection, acute chest syndrome, and stroke. Thus, the introduction of advanced products in the market is expected to drive the growth of the North America sickle cell disease market over the forecast period.
Market Dynamics
The key players in the pharmaceutical industry are focusing on the development of technologically advanced drugs for the treatment of sickle cell disease. Thus, the introduction of such advanced products in the market is expected to the drive growth of the North America sickle cell disease market over the forecast period. F006F r instance, on June 21, 2023, bluebird bio, Inc., a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) for priority review. Lovo-cel is a potentially transformative one-time gene therapy for individuals living with Sickle Cell Disease (SCD) for ages 12 and older who have a history of Vaso-occlusive Events (VOEs). It is specifically designed to treat the underlying cause of SCD through the addition of a functional gene that enables the production of anti-sickling adult hemoglobin and is the most deeply studied gene therapy in development for this disease.
Key features of the study:
- This report provides an in-depth analysis of the North America sickle cell disease market and provides market size (US$ Million) and Compound Annual Growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the North America sickle cell disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- The key companies covered as a part of this study include Novartis International AG, Bristol-Myers Squibb Company, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., IMARA, , bluebird bio, Inc., CRISPR Therapeutics, Scribe Therapeutics Inc., Fulcrum Therapeutics, Inc., HPC International, Editas Medicine, Inc., Nicox SA, Fera Pharmaceuticals, and Tessera Therapeutics
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The North America sickle cell disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America sickle cell disease market
Detailed Segmentation:
- By Disease Type:
- Sickle Cell Anemia
- Sickle Beta Thalassemia
- Sickle Hemoglobin C Disease
- By Drug Type:
- Hydroxyurea
- L-glutamine
- Crizanlizumab
- Pain-relievers
- Voxelotor
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.S.
- Canada
- Company Profiles
- Novartis International AG
- Bristol-Myers Squibb Company
- Global Blood Therapeutics, Inc.
- Pfizer Inc.
- Emmaus Life Sciences, Inc.
- ADDMEDICA
- Sangamo Therapeutics, Inc.
- Acceleron Pharma, Inc.
- Agios Pharmaceuticals, Inc.
- Chiesi Farmaceutici S.p.A.
- Vertex Pharmaceuticals, Inc.
- IMARA, Inc.
- bluebird bio, Inc.
- CRISPR Therapeutics
- Scribe Therapeutics Inc.
- Fulcrum Therapeutics, Inc.
- HPC International
- Editas Medicine, Inc.
- Nicox SA
- Fera Pharmaceuticals
- Tessera Therapeutics
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER'S Analysis
- Pipeline Analysis
4. North America Sickle Cell Disease Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. North America Sickle Cell Disease Market, By Disease Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Sickle Cell Anemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Sickle Beta Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Sickle Hemoglobin C Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
6. North America Sickle Cell Disease Market, By Drug Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hydroxyurea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- L-glutamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Crizanlizumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Pain-relievers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Voxelotor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
7. North America Sickle Cell Disease Market, By Distribution Channel, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
8. North America Sickle Cell Disease Market, By Country, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- U.S.
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Canada
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
9. Competitive Landscape
- Company Profiles
- Novartis International AG*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Global Blood Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Emmaus Life Sciences, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- ADDMEDICA
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sangamo Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Acceleron Pharma, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Agios Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Chiesi Farmaceutici S.p.A.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Vertex Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- IMARA, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- CRISPR Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Scribe Therapeutics Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Fulcrum Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- HPC International
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Editas Medicine, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Nicox SA
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Fera Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Tessera Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
10. Section
- References
- Research Methodology
- About us and Sales Contact
